

In the Specification

At page 35, line 7, please enter the amended paragraph as follows:

A1

As illustrated in Figure 4, induction of alkaline phosphatase mRNA in an assay of the invention using the estradiol-inducible zinc finger was measured.

In the Claims

Please enter claims 82-85 as presented below in amended form:

A2

82. A transcription factor regulator identified by a method comprising the steps of:

a) contacting a compound suspected of being a transcription factor regulator with a cell having a nucleus and containing a membrane-bound, constitutively active transcription factor produced by expression of a nucleic acid construct comprising an expression vector containing:

- i) a constitutively active domain;
- ii) a synthetic DNA binding domain that binds to a nucleic acid sequence and activates transcription of an endogenous gene; and
- iii) a membrane anchoring domain that contains a protease cleavage site, wherein the constitutively active domain is operably linked to the DNA binding domain such that the transcription factor is active in an unregulated fashion;

- A2
conf.
- b) stimulating activity of a protease by the compound to release the transcription factor from the membrane, thereby allowing the transcription factor to translocate to the nucleus; and
 - c) measuring expression of a gene under promotional control of the membrane-bound transcription factor, whereby an increase or decrease in expression of the gene is indicative that the compound is a transcription factor regulator.

83. A pharmaceutical composition comprising a transcription factor regulator of claim 82.

84. A transcription factor regulator identified by a method comprising the steps of:

a) contacting a compound suspected of being a transcription factor regulator with an extracellular ligand and a cell having a nucleus and containing a membrane-bound, constitutively active transcription factor produced by expression of a nucleic acid construct comprising an expression vector containing:

- i) a constitutively active domain;
- ii) a synthetic DNA binding domain that binds to a nucleic acid sequence and activates transcription of an endogenous gene; and
- iii) a membrane anchoring domain that contains a protease cleavage site, wherein the constitutively active domain is operably

linked to the DNA binding domain such that the transcription factor is active in an unregulated fashion;

- A2
conclude
- b) stimulating activity of a protease by either the compound or the ligand to release the transcription factor from the membrane, thereby allowing the transcription factor to translocate to the nucleus; and
 - c) measuring expression of a gene under promotional control of the membrane-bound transcription factor, whereby an increase or decrease in expression of the gene is indicative that the compound is a transcription factor regulator.

85. A pharmaceutical composition comprising a transcription factor regulator of claim 84.
